Aridis uses human antibodies to fight against “time bomb” of antibiotic resistance

Although antibodies have gained plenty of ground in recent years as vehicles for cancer therapies, Aridis Pharmaceuticals wants to use them as nature intended – to fight infection. “These are human monoclonal antibodies being investigated as anti-infectives to treat bacterial infections associated with pneumonia,” founder &CEO Vu Truong told Drug Delivery Business News, referring to the company’s projects that are in pivotal trials. “The fundamental reason is that this is exactly what the antibody is designed to do – that is, to fight infection,” he explained. Get the full story at our sister site, Drug Delivery Business News. The post Aridis uses human antibodies to fight against “time bomb” of antibiotic resistance appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Hospital Care Pharmaceuticals Research & Development aridispharmaceuticals Source Type: news

Related Links:

Publication date: Available online 13 April 2018Source: Respiratory InvestigationAuthor(s): Kohei Otsubo, Isamu Okamoto, Naoki Hamada, Yoichi NakanishiAbstractInterstitial lung disease (ILD) is a risk factor for lung cancer development and is frequently observed in patients with lung cancer. Individuals with ILD have been excluded from most prospective clinical trials of lung cancer therapies because of the risk of ILD acute exacerbation. Thus, the optimal anticancer drug treatment for such patients has yet to be established. Tyrosine kinase inhibitors are avoided for the treatment of advanced non–small cell lung can...
Source: Respiratory Investigation - Category: Respiratory Medicine Source Type: research
Discussion of advocacy for the cause is a usual feature of our community, as we try things and attempt to make progress in persuading the world that rejuvenation research is plausible, practical, and necessary. There are more people engaged in advocacy now than at any time in the past decade, and so discussions of strategy come up often. New ventures kicked off in 2017 include the Geroscience online magazine, and among the existing ventures the LEAF / Lifespan.io volunteers seem to be hitting their stride. The mainstream media continues to be as much a hindrance as a help, and where it is a help you will usually find Aubre...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
CONCLUSION: Poor response against pneumococcal vaccines increases the susceptibility of respiratory diseases in these patients. In patients with NHL treated with RTX, the benefits achieved with IVIg replacement for the control of recurrent infectious diseases is of paramount importance. Clinicians dealing with monoclonal antibodies against cancer therapy, especially RTX, should be aware of the increasing risks for symptomatic induced hypogammaglobulinemia and respiratory infections. PMID: 29094629 [PubMed - as supplied by publisher]
Source: Immunopharmacology and Immunotoxicology - Category: Allergy & Immunology Tags: Immunopharmacol Immunotoxicol Source Type: research
Conclusions The incidence of post-bronchoscopy pneumonia in patients with lung cancer was not rare and associated with adverse effects on the clinical course. A simple 3-point predictive score identified patients with lung cancer at high risk of post-bronchoscopy pneumonia prior to the procedure.
Source: Respiratory Investigation - Category: Respiratory Medicine Source Type: research
Introduction: Interstitial lung diseases induced by anticancer agents (ILD-AA) are known to be a rare adverse effect of anti-cancer therapy. However, predictive prognostic fibrotic biomarkers of ILD-AA have not been identified in patients with advanced lung cancer (ALC).Aim: To analyze the association between serum fibrotic biomarkers, including KL-6 and surfactant protein D (SP-D), onset and types of ILD-AA by chest high resolution computed tomography (HRCT) findings in ALC patients.Methods: KL-6 and SP-D were defined as the difference between the values of KL-6 and SP-D level at the onset of ILD-AA and their respective v...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: 1.5 Diffuse Parenchymal Lung Disease Source Type: research
This study describes pulmonary outcomes among childhood cancer survivors and evaluates their impact on daily activities. METHODSThe incidence of pulmonary outcomes (asthma, chronic cough, emphysema, lung fibrosis, oxygen need, and recurrent pneumonia) reported among 5‐year cancer survivors (n = 14,316) and the incidence of death due to pulmonary causes among all eligible survivors (n = 20,690) in the Childhood Cancer Survivor Study were compared with those for sibling controls (n = 4027) with cumulative incidence, standardized mortality ratio (SMR), and piecewise exponential mode...
Source: Cancer - Category: Cancer & Oncology Authors: Tags: Original Article Source Type: research
No abstract available
Source: Oncology Times - Category: Cancer & Oncology Tags: News Source Type: research
This study determined the frequency of drug-related pneumonitis during mammalian target of rapamycin (mTOR) inhibitor therapy in Waldenström macroglobulinemia patients and investigated the imaging characteristics and radiographic patterns of pneumonitis. MATERIALS AND METHODS: A total of 40 patients (23 men, 17 women; 43-84 years old) with Waldenström macroglobulinemia treated in 2 trials of the mTOR inhibitor everolimus were retrospectively studied. Chest computed tomography (CT) scans during therapy were reviewed for abnormalities suspicious for drug-related pneumonitis by the consensus of three radiologis...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
Value-based health care has risen to the top of the health policy agenda, as public and private payers search for ways to improve outcomes. The value principle---reimbursing hospitals, physicians, and other health care providers for quality or quality improvement that also help lower costs---aligns incentives between payers and providers. It’s time to apply this principle in oncology. Background Medicare implemented value-based payment for hospitals in 2012. Reimbursement is based in part on how well the hospital performed on three sets of measure: process of care, patient satisfaction, and mortality. About 1,231 hos...
Source: Health Affairs Blog - Category: Health Management Authors: Tags: Costs and Spending Equity and Disparities Health Policy Lab Payment Policy Quality cancer care oncology outcomes value based care Source Type: blogs
More News: Cancer | Cancer & Oncology | Cancer Therapy | Hospitals | Pneumonia